Today: August 2, 2015, 4:25 pm
  
China HIV market: New market research published
companiesandmarkets.com
companiesandmarkets.com
PharmaPoint: HIV - China Drug Forecast and Market Analysis to 2022 - a new market research report on companiesandmarkets.com

 

PR-Inside.com: 2014-03-12 20:09:03
PharmaPoint: HIV - China Drug Forecast and Market Analysis to 2022 - GlobalData has released its new Country report, "PharmaPoint: HIV - China Drug Forecast and Market Analysis to 2022". Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance.

Unlike the seven major markets, the market in China mostly represents revenues generated from the sale of generics. GlobalData estimates that ViiV will launch its pipeline candidate, 572-Trii, as a novel STR in an attempt to break into this market. The NRTI class is represented mainly by generic Combivir, followed by generic lamivudine, stavudine, and generic Trizivir. The use of Gilead´s Viread is expanding mainly through its combination with lamivudine.

Scope

- Overview of HIV including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in China from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting China HIV market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HIV
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in China

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.


Press Information


Published by
Mike King
London: +44 (0) 203 086 8600
e-mail
www.companiesandmarkets.com
Related Articles

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.